GLUCAGON KIT

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

GLUCAGON (RECOMBINANT DNA ORIGIN)

Pieejams no:

ELI LILLY CANADA INC

ATĶ kods:

H04AA01

SNN (starptautisko nepatentēto nosaukumu):

GLUCAGON

Deva:

1MG

Zāļu forma:

KIT

Kompozīcija:

GLUCAGON (RECOMBINANT DNA ORIGIN) 1MG

Ievadīšanas:

INTRAMUSCULAR

Vienības iepakojumā:

1 ML

Receptes veids:

Schedule D

Ārstniecības joma:

GLYCOGENOLYTIC AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0142861001; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2023-12-18

Produkta apraksts

GLUCACON (rDNA Origin) Product Monograph
Page 1 of 32
PRODUCT MONOGRAPH
GLUCAGON
GLUCAGON FOR INJECTION, RDNA ORIGIN
1 MG GLUCAGON PER VIAL
Sterile Lyophilized Powder and Diluent
Hyperglycemic Agent
©
Eli Lilly Canada Inc.
3650 Danforth Avenue
Toronto, Ontario
M1N 2E8
1-888-545-5972
Date of Approval:
July 9, 2012
www.lilly.ca
Submission Control No: 139332
GLUCACON (rDNA Origin) Product Monograph
Page 2 of 32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
6
DRUG INTERACTION
............................................................................................................
8
DOSAGE AND ADMINISTRATION
.....................................................................................
9
OVERDOSAGE
......................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 12
STORAGE AND STABILITY
...............................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................... 13
PART II: SCIENTIFIC INFORMATION
..............................................................................
14
PHARMACEUTICAL INFORMATION
...............................................................................
14
CLINICAL TRIALS
...........................................................................................................